Merck Oncology Clinical Trials for Bladder Cancer

Merck is passionate about improving health. We are committed to accelerating every step of the journey in our quest to bring treatment options to people with cancer. These clinical trials for bladder cancer are investigating different study medications alone, or in combination with other study medications, or standard of care therapy, to see if they can help prevent, find, or treat cancer.

Participating in a clinical trial is an important decision. Anyone participating in a trial should know as much as possible about what is being studied, what risks are involved and what potential benefits may be gained before deciding to enroll. If you are interested in participating in a clinical trial, please talk to your doctor first.

You can also call our clinical trial information center at 1-888-577-8839 to learn more.

Active Clinical Trials

Trial Description Trial Number Condition Phase Status
Study of First-line Pembrolizumab With Lenvatinib in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy
7902-011 Urothelial Carcinoma Phase 3 Recruiting
Study of Pembrolizumab in Participants With High Risk Non-muscle Invasive Bladder Cancer
057 Bladder Cancer Phase 2 Recruiting
Efficacy and Safety of Pembrolizumab in Combination With Bacillus Calmette-Guerin in High-Risk Non-Muscle Invasive Bladder Cancer
676 High-risk Non-muscle Invasive Bladder Cancer Phase 3 Recruiting
Perioperative Pembrolizumab Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer
866 Urinary Bladder Cancer, Muscle-invasive Phase 3 Recruiting
Perioperative Pembrolizumab Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer
905 Urinary Bladder Cancer, Muscle-invasive Phase 3 Recruiting
A Study of Pembrolizumab Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer
045 Urothelial Cancer Phase 3 Active, not recruiting
Study of Pembrolizumab in Participants With Advanced Urothelial Cancer
052 Urothelial Cancer Phase 2 Active, not recruiting
Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma
361 Urothelial Carcinoma Associated 1 RNA, Human Phase 3 Active, not recruiting

Clinical Trials: Important Information to Consider

There is a lot to consider when deciding whether to participate in a clinical study. Any clinical study includes risks, which the study doctor will review with you. Make sure you understand the risks before participating.